2,2,2-三氟-N-(5-甲基-噻唑-2-基)-乙酰胺 | 820230-84-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2,2,2-三氟-N-(5-甲基-噻唑-2-基)-乙酰胺
• 英文名称: 2,2,2-trifluoro-N-(5-methyl-1,3-thiazol-2-yl)acetamide
• CAS: 820230-84-0
• 化学式: C₆H₅F₃N₂OS
• 分子量: 210.18
• InChiKey: UEBAULPFRPBPLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,2,2-三氟-N-(5-甲基-噻唑-2-基)-乙酰胺 、 (氯甲基)萘 在 potassium iodide potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以79.2%的产率得到2,2,2-trifluoro-N-[(2Z)-5-methyl-3-(1-naphthylmethyl)-1,3-thiazol-2(3H)-ylidene]acetamide
  参考文献：
  名称：

  EP1640369

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-5-甲基噻唑 、 三氟乙酸酐 以 甲苯 为溶剂， 反应 2.0h， 以69.1%的产率得到2,2,2-三氟-N-(5-甲基-噻唑-2-基)-乙酰胺
  参考文献：
  名称：

  EP1640369

  摘要：

  公开号：

文献信息

• Thiazolimine compound and oxazolimine compound
  申请人：Yamaguchi Hiroki

  公开号：US20070105908A1

  公开（公告）日：2007-05-10

  A compound represented by the formula (1): (wherein X represents sulfur or oxygen; R 1 and R 2 each represents a group represented by the formula —Y 3 -Z, etc.; Y 3 represents a single bond or (un)substituted alkylene; Y 1 and Y 2 each represents (un)substituted alkylene; Z represents hydrogen, an (un)saturated monocyclic heterocyclic group, etc.; M represents carboxy, etc.; Q represents o-phenylene, etc.; and A represents an (un)saturated monocyclic hydrocarbon group, etc.), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are compounds having chymase inhibitory activity and useful as a therapeutic agent for hypertension, cardiac failure, etc.

  化合物的化学式为(1):(其中X代表硫或氧；R1和R2分别代表化学式为—Y3-Z等的基团；Y3代表单键或(未)取代的烷基；Y1和Y2分别代表(未)取代的烷基；Z代表氢、(未)饱和的单环杂环基团等；M代表羧基等；Q代表o-苯基等；A代表(未)饱和的单环烃基团等)、其前药或其药学上可接受的盐。它们是具有chymase抑制活性的化合物，并且可用作治疗高血压、心力衰竭等疾病的治疗剂。
• METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
  申请人：Almstead Neil

  公开号：US20120202763A1

  公开（公告）日：2012-08-09

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

  本文介绍了选择性抑制人类血管内皮生长因子（VEGF）病理性产生的化合物以及包含这些化合物的组合物。本文还介绍了抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的化合物以及包含这些化合物的组合物。同时，本文还介绍了使用这些化合物减少VEGF的方法以及使用这些化合物治疗癌症和非肿瘤性疾病的方法。本文还介绍了使用这些化合物抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的方法以及使用这些化合物治疗病毒感染的方法。这些化合物可以作为单一治疗剂或与一个或多个其他治疗剂联合使用，用于治疗需要这些治疗的人类。
• THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1640369A1

  公开（公告）日：2006-03-29

  A compound represented by the formula (1): (wherein X represents sulfur or oxygen; R1 and R2 each represents a group represented by the formula -Y3-Z, etc.; Y3 represents a single bond or (un)substituted alkylene; Y1 and Y2 each represents (un)substituted alkylene; Z represents hydrogen, an (un)saturated monocyclic heterocyclic group, etc.; M represents carboxy, etc.; Q represents o-phenylene, etc.; and A represents an (un)saturated monocyclic hydrocarbon group, etc.), a prodrug thereof, or a pharmaceutically acceptable salt of either. They are compounds having chymase inhibitory activity and useful as a therapeutic agent for hypertension, cardiac failure, etc.

  式 (1) 所代表的化合物： (其中 X 代表硫或氧；R1 和 R2 各自代表由式-Y3-Z 等表示的基团；Y3 代表单键或(未)取代亚烷基；Y1 和 Y2 各自代表(未)取代亚烷基；Z 代表氢、(未)饱和单环杂环基团等；M 代表羧基等；Q 代表邻苯基等；A 代表(未)饱和单环烃基团等)。M代表羧基等；Q代表邻苯基等；A代表（未）饱和的单环烃基等）、其原药或二者的药学上可接受的盐。它们是具有糜蛋白酶抑制活性的化合物，可作为高血压、心力衰竭等的治疗药物。
• METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION
  申请人：PTC Therapeutics, Inc.

  公开号：US20200317668A1

  公开（公告）日：2020-10-08

  Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of inhibiting or reducing viral replication or the production of viral RNA or DNA or viral protein using such Compounds, and methods for treating viral infections, such as an RNA virus belonging to the family Coronaviridae, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
• US9351964B2
  申请人：——

  公开号：US9351964B2

  公开（公告）日：2016-05-31